THE BEA SCORE IN CHRONIC HEPATITIS B AND DELTA
DOI:
https://doi.org/10.11603/1811-2471.2016.v0.i4.7097Keywords:
chronic hepatitis delta, BEA score, liver laboratory syndromes.Abstract
Purpose: To study the BEA score (Baseline Event-anticipation score) and its correlation with biological signs of liver laboratory syndromes in the patients with chronic hepatitis B and Delta.
Material and method. There were investigated prospectively 58 Caucasian patients with chronic hepatitis B and Delta (CHD), 28 women and 30 men, and 10 Caucasian patients with viral liver cirrhosis Delta (LCD). BEA score was estimated using the online calculator (http://hepatitis-delta.org/physicians-and-scientists/calculators/).
There was estimated the BEA score and the indicators of the biological liver syndromes were studied. The correlation analysis was performed (after Spearman) between the score values of BEA parameters and the biological liver syndromes.
Results: It was established the direct correlation of the BEA score with the values of the levels of serum gamma-glutamyl transferees and with the serum total bilirubin in patients with HCD. In patients with LCD there was determined direct correlation of the BEA score with the total bilirubin and inverse correlation with the serum albumin values.
Conclusions: We recommend modifying the BEA score by adding the albumin and GGT as predictors for developing complications related to liver disease.
References
Calle Serrano B, Grosshennig A, Homs M, et al. Development and evaluation of a baseline-event-anticipation score for hepatitis delta. Journal of Viral Hepatitis, 2014; 21: e154-e163.
Elham Shirvani-Dastgerdi, Frank Tacke, Molecular interactions between hepatitis B virus and delta virus, World J Virol 2015 May 4(2): 36-41.
Heidrich B, Serrano BC et al. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver Int 2012; 32: 1415-1425.
Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011; 378: 73-85.
Manesis EK, Vourli G, Dalekos G, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol 2013; 59: 949–56.
Mauss Stefan et. al. Hepatology. A clinical textbook. 7th Edition, 2016, 709 pag.
Price J. An update on hepatitis B, D, and E viruses. Top Antivir Med 2014; 21: 157-163.
Romeo R, Foglieni B, Casazza G, Spreafi co M, Colombo M, Prati D. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS One 2014; 9: e92062.
Zaigham Abbas, Minaam Abbas, Sarim Abbas, Lubna Shazi, Hepatitis D and hepatocellular carcinoma, World J Hepatol 2015 April, 7(5): 777-786.
Wranke A, Hardtke S, Wedemeyer H. Aktuelles Management der Hepatitis Delta. Journal für Gastroenterologische und Hepatologische Erkrankungen. 2015; 13 (4), 11-17.
Wranke A, Heidrich B, Ernst S, et al. Anti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS One 2014; 9: e101002.
http://hepatitis-delta.org/physicians-and-scientists/calculators/ - BEA-Score Calculator
